|Bid||248.17 x 800|
|Ask||248.21 x 1000|
|Day's Range||246.30 - 249.85|
|52 Week Range||198.64 - 258.45|
|Beta (5Y Monthly)||0.56|
|PE Ratio (TTM)||21.12|
|Forward Dividend & Yield||7.76 (3.12%)|
|Ex-Dividend Date||Aug 17, 2022|
|1y Target Est||N/A|
Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
The U.S. Senate Finance Committee is widening its investigation into the tax practices of U.S. drugmakers to include Amgen Inc, according to a letter sent on Thursday by the committee's chairman, Senator Ron Wyden. Amgen is already in the crosshairs of the U.S. Internal Revenue Service over its tax practices, particularly how it allocates profits between the U.S. and Puerto Rico. The IRS is after more than $10 billion in back taxes and penalties the California-based biotech firm, although Amgen has said it believes the proposed adjustments and penalties are without merit.
Earnings updates from Amgen (AMGN) and its ChemoCentryx (CCXI) acquisition are a few key highlights from the biotech sector during the past week.